Kobayashi Pharmaceutical : FY2016 3Q Financial Statement

0a7d6141-e820-4129-a1ad-2e9c46e94868.pdf Summary of Financial Statements (Japanese GAAP) (Consolidated) Financial Results for the 3rd Quarter of the Fiscal Year Ending March 31, 2016

January 25, 2016

Listed exchanges : Tokyo

Listed company name: Kobayashi Pharmaceutical Co., Ltd. Code : 4967

URL : http://www.kobayashi.co.jp Representative officer: Akihiro Kobayashi, President & COO Contact : Satoshi Yamane,

Executive Director & Senior General Manager, Corporate Administration Headquarters Tel : [phone]

Expected date for submitting quarterly securities report : February 5, 2016 Preparation of supplementary explanation documents for quarterly financial results : None

Holding of an analyst meeting for quarterly financial results : None

(Any fraction less than 1 million yen is rounded down to the nearest million yen.)

1. Consolidated Results for 3rd Quarter of Fiscal Year Ending March 31, 2016 (April 1, 2015 to December 31, 2015)

   
   

2. Consolidated Operating Results (accumulation)

   (% figures represent changes from same period in previous year.)

   Q3 of FY ending March 31, 2016 Q3 of FY ended March 31, 2015

   
   

   Net sales	104,608	millions of yen	7.7	%	97,154	millions of yen	1.5	%
   Operating income	16,675	11.5	14,950	-0.8
   Ordinary income	16,555	5.1	15,751	1.6
   Net income attributable to owners of the parent	12,454	16.7	10,672	4.1
   Net income per share	305.24	yen	261.80	yen
   Net income per share after full dilution	304.78	yen	

   (Note) Comprehensive income: Q3 of FY ending March 31, 2016: 14,120 million yen (24.1%)

   Q3 of FY ended March 31, 2015: 11,375 million yen (-8.3%)

   
   

3. Consolidated Financial Position




Q3 of FY ending March 31, 2016		As of March 31, 2015
Total assets	195,244	millions of yen	186,331	millions of yen
Net assets	147,620	139,611
Shareholders' equity ratio	75.5	%	74.8	%
Net assets per share	3,633.52	yen	3,423.54	yen

(Reference) Shareholders' equity

Q3 of FY ending March 31, 2016: 147,449 million yen As of March 31, 2015: 139,397 million yen

4. Dividends

   
   

   Year ended March 2015		Year ending March 2016		Year ending March 2016 (forecasts)
   Dividends per share
   Q1 end		
   Q2 end	44.00	yen	48.00	yen
   Q3 end		
   Year-end	46.00	46.00	yen
   Total	90.00	94.00

   (Note) Revision of the latest dividend forecast: None

   
   

5. Forecasts of Consolidated Operational Results for Year Ending March 31, 2016

(April 1, 2015 to March 31, 2016)




(Percentage figures represent changes from previous period.)

FY ending March 31, 2016




Net sales	136,500	millions of yen	6.4 %
Operating income	19,200	7.2
Ordinary income	18,900	0.3

Net income attributable to

owners of the parent 13,3006.8

Earnings per share 325.95 yen




(Note) Revision of the latest forecasts of operational results: None




* Notes

1. Changes in significant subsidiaries during the period (Changes in specified subsidiaries accompanying change of scope of consolidation): None

   Newly consolidated: - (company name: ), Eliminated from the scope of consolidation: - (company name: )

   
   

2. Adoption of special accounting methods for preparing quarterly consolidated financial statements: None

   
   

3. Change in accounting policies, changes in accounting estimates and retrospective restatement

    Changes in accounting policies associated with revision of accounting standards: Yes

    Changes in accounting policies other than : None

    Changes in accounting estimates: None

    Retrospective restatement: None

   For details, please refer to 2. Items concerning Summary Information (Notes) (3) Changes in accounting policies, changes in accounting estimates and retrospective restatement on page 4 of the attachment.

   
   

   Q3 of FY ending March 31, 2016	42,525,000 shares	FY ended March 31, 2015	42,525,000 shares
   Q3 of FY ending March 31, 2016	1,944,775 shares	FY ended March 31, 2015	1,807,775 shares
   Q3 of FY ending March 31, 2016	40,803,759 shares	Q3 of FY ended March 31, 2015	40,766,913 shares

4. Issued shares (common shares)

 Number of shares issued at period-end (including treasury stock):

 Number of shares of treasury stock at period-end

 Average number of shares outstanding during period (consolidated cumulative quarters)

• Information on implementation of quarterly review procedures

  This brief report of quarterly financial statements is not subject to audit procedures under the Financial Instruments and Exchange Act. Audit procedures concerning quarterly financial statements have not been completed under the Financial Instruments and Exchange Act at the date of disclosure of this brief report of quarterly financial statements.

  
  

• Explanation on appropriate use of forecasts of business results and other special items

The forward-looking statements in this document concerning forecasts of business results are based on information available to the Company and assumptions considered reasonable by the Company. Please note that actual business results may differ significantly from the forecast due to various factors. Concerning assumptions for forecasting business results and precautionary statements, please refer to "1. Qualitative Information on Quarterly Results, (3) Explanation of future forecast information, such as forecast of consolidated results" on page 3 of the attachment.

Kobayashi Pharmaceutical Co., Ltd. (4967)

Summary of Financial Statements 3rd Quarter of the Fiscal Year Ending March 31, 2016




Table of Contents for Attachment

1. Qualitative Information on Quarterly Results 2

2. Explanation of operational results 2

3. Explanation of financial position 3

4. Explanation of future forecast information, such as forecast of consolidated results 3

5. Items concerning Summary Information (Notes) 4

6. Changes in significant subsidiaries during the period 4

7. Adoption of special accounting methods for preparing

   quarterly consolidated financial statements 4

8. Changes in accounting policies, changes in accounting estimates

   and retrospective restatement 4

9. Quarterly Financial Statements 5

10. Consolidated quarterly balance sheet 5

11. Consolidated quarterly statements of income and consolidated quarterly statements of comprehensive income 7

    Consolidated quarterly statements of income

    For the first nine-month period of the fiscal year ending March 31, 2016 7

    Consolidated quarterly statements of comprehensive income

    For the first nine-month period of the fiscal year ending March 31, 2016 8

12. Notes on quarterly consolidated financial statements 9

(Notes on assumption of going concern) 9

(Notes on significant changes in shareholders' equity) 9

(Segment information, etc.) 9

(Significant subsequent events) 10




1